# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-052497
Filing Date
2025-04-09
Accepted
2025-04-09 16:04:19
Documents
61
Period of Report
2025-02-28

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | neog-20250228.htm iXBRL | 10-Q | 2457154
2 | EX-31.1 | neog-ex31_1.htm | EX-31.1 | 15468
3 | EX-31.2 | neog-ex31_2.htm | EX-31.2 | 15262
4 | EX-32 | neog-ex32.htm | EX-32 | 12256
5 | GRAPHIC | img194654855_0.jpg | GRAPHIC | 646845
| Complete submission text file | 0000950170-25-052497.txt |  | 10591851

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | neog-20250228.xsd | EX-101.SCH | 1195392
63 | EXTRACTED XBRL INSTANCE DOCUMENT | neog-20250228_htm.xml | XML | 1767104

Mailing Address 620 LESHER PLACE LANSING MI 48912
Business Address 620 LESHER PLACE LANSING MI 48912 5173729200
NEOGEN CORP (Filer) CIK: 0000711377 (see all company filings)

EIN.: 382367843 | State of Incorp.: MI | Fiscal Year End: 0531
Type: 10-Q | Act: 34 | File No.: 000-17988 | Film No.: 25825204
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)